Abstract:
A total of 309 (138 males and 171 females) end-stage renal disease patients who underwent implantation of early cannulation arteriovenous grafts (Acuseal) for hemodialysis in Nanfang Hospital, Southern Medical University between December 2016 and May 2021 were retrospectively included. The age of patients was (61.5±10.3) years. There were 244 patients (119 males and 125 females) who received regular follow-up. During the follow-up period, 24 patients died. Perioperative complications included graft infection (4.5%, 11/244), hematoma (4.5%, 11/244) and steal syndrome (4.1%, 10/244). No seroma or anastomotic rupture occurred. The rates of the first postoperative puncture time within 24 h, 48 h and 72 h after implantation were 42.2%(103/244), 32.4% (79/244) and 16.4% (40/244), respectively. The Kaplan-Meier survival analysis showed that the primary patency rates at 6 months and 12 months were 66.5% and 48.4%, respectively, and the secondary patency rates at 6 months and 12 months were 96.7% and 91.8%, respectively. The current study indicates that the Acuseal graft is safe for vascular access in patients requiring hemodialysis, with satisfactory patency and acceptable complication rates at 1-year follow-up.
回顾性分析2016年12月至2021年5月在南方医科大学南方医院因血液透析植入即穿型人工血管构建动静脉移植物内瘘的309例终末期肾病患者(男138例,女171例)的临床资料。患者年龄(61.5±10.3)岁,其中244例患者(男119例,女125例)得到规律随访。随访期间24例患者死亡。309例患者中围手术期并发症包括移植物感染11例(4.5%),穿刺相关血肿11例(4.5%),窃血综合征10例(4.1%),无血清肿、吻合口破裂及移植物内瘘血栓形成发生。植入人工血管后24、48、72 h内进行第1次穿刺透析的比例分别为42.2%(103/244)、32.4%(79/244)、16.4%(40/244)。Kaplan-Meier生存分析结果显示,6、12个月初级通畅率分别为66.5%、48.4%,6、12个月次级通畅率分别为96.7%、91.8%。本研究结果显示即穿型人工血管移植物可安全地用于终末期肾病患者作为血管通路,其中12个月的随访结果满意。.